S85 Clinical Impact of Vedolizumab Treatment in Patients With Ulcerative Colitis: Evidence from a Real-World Study in Mexico
Notice bibliographique
Résumé
Background: Ulcerative colitis (UC) is a chronic inflammatory disease that primarily affects the colonic mucosa, significantly impairing patient’s quality of life. Vedolizumab (VDZ), a humanized monoclonal antibody, targets the α4β7 integrin on leukocytes, inhibiting their interaction with mucosal addressin cell adhesion molecule 1 (MAdCAM-1) and thereby restricting lymphocyte migration to intestinal tissue. VDZ is indicated for moderate to severe UC in patients who have not responded to conventional therapies or tumor necrosis factor-α antagonists and has demonstrated efficacy as a first-line treatment for UC. However, real-world data on VDZ’s effectiveness in Latin America and Mexico is limited. This study aims to assess the impact of VDZ treatment over a 12-week period in UC patients by evaluating both clinical and biochemical parameters. Methods: A cross-sectional, analytical study was conducted involving 27 patients from the Inflammatory Bowel Disease Clinic at the General Hospital of Mexico “Dr. Eduardo Liceaga,” who were diagnosed with UC and treated with VDZ. Data collected included demographic information, disease characteristics, extraintestinal manifestations, and biochemical markers such as C-reactive protein (CRP) levels and fecal calprotectin (FCP). Disease activity was measured using the Truelove and Witts scale. Descriptive statistics summarized the demographic and clinical characteristics of the patients. Continuous variables were presented as means with standard deviations or medians with interquartile ranges, as appropriate. Paired t-tests or Wilcoxon signed-rank tests were used to compare clinical and biochemical parameters before and after treatment, depending on data distribution. A significance level of p < 0.05 was used, and 95% confidence intervals (CIs) were calculated for mean differences (∆). Results: The study cohort was predominantly male (59.3%), with a mean age of 40.11 ± 13.28 years. According to the Montreal classification, 66.7% of patients had pancolitis (E3). Notably, 96.3% of patients had no previous exposure to biological therapies. After 12 weeks of treatment, there was a significant reduction in the Truelove and Witts score from 13.4 ± 2.72 to 9.9 ± 1.4 (∆ = -3.5, 95% CI: -4.6 to -2.4, p < 0.001) and in fecal calprotectin levels, which decreased from 1559 (449 - 2200) to 256 (58.1 - 586) (∆ = -1303, 95% CI: -1750 to -856, p < 0.001). Conversely, CRP levels did not exhibit a significant change. Conclusions: Vedolizumab treatment over a 12-week period significantly improved both clinical and biochemical parameters in UC patients, as evidenced by reductions in the Truelove and Witts score and fecal calprotectin levels. These findings underscore the effectiveness and safety of VDZ as a first-line therapy for UC, particularly in patients without prior exposure to biological treatments. This study provides valuable insights into the application of VDZ in Latin America and Mexico, where real-world data is scarce.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,002 | 0,003 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,001 |
| Bibliométrie | 0,001 | 0,001 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,001 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,002 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».